west virginia tirzepatide lawsuit Compounded' weight-loss drugs are a growing problem for state regulators • Watch Mounjaro & Zepbound NAION Lawsuit

Nat Rev Dis Primers (2016) 2:16065

1,4 Real-world results may differ

Article overview and relevance to your clinical practice The first oral formulation of a glucagon-like peptide-1 receptor agonist, oral semaglutide, has recently been introduced for the treatment of type 2 diabetes (T2D) and presents an additional option for primary care clinicians treating people with T2D

In healthy adults, DAC-modified CJC-1295 produced dose-dependent GH increases for six days or more and IGF-1 increases for nine to eleven days after a single injection

These include: Increased appetite and food cravings , which may work against Wegovy's appetite-suppressing effects Insulin resistance and elevated blood glucose levels , potentially leading to steroid-induced diabetes Fluid retention and weight gain , particularly in the face, neck, and trunk (cushingoid features) Redistribution of body fat to central areas Muscle wasting , which can reduce metabolic rate Patients taking both medications may experience reduced weight loss efficacy compared to those taking Wegovy alone, though the appetite-suppressing effects of Wegovy may help mitigate steroid-induced hunger